NASDAQ$WBA
Walgreens Boots Alliance Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Walgreens' Q4 2022 earnings exceeded expectations, with long-term targets raised for the U.S. Healthcare segment.
Walgreens Boots Alliance reported Q4 sales of $32.4 billion, a 5.3% decrease year-over-year. The company's loss per share was $0.48, while adjusted EPS decreased by 31.8% to $0.80. Despite these declines, Walgreens is raising its U.S. Healthcare fiscal 2025 sales target and expects low-teens adjusted EPS growth in fiscal year 2025 and beyond.
- Q4 sales decreased by 5.3% year-over-year to $32.4 billion.
- Loss per share from continuing operations was $0.48, a decrease of $0.89 from the year-ago quarter.
- Adjusted EPS decreased 31.8% to $0.80, down 30.0% on a constant currency basis.
- Raising U.S. Healthcare fiscal 2025 sales target to $11 billion to $12 billion, with the segment expected to achieve positive adjusted EBITDA by fiscal year 2024.
Headline financials
Revenue & EPS history
Walgreens · Revenue · Quarterly
$32.4B
Revenue by segment
Walgreens · $7.76B total across 2 segments · Q4 2023
- International$5.78B—74.6%
- U.S. Healthcare$1.97B+217.0%25.4%
Forward guidance
Walgreens Boots Alliance expects an adjusted EPS of $4.45 to $4.65 for the full fiscal year 2023. The company is also raising the U.S. Healthcare fiscal year 2025 sales target to $11 billion to $12 billion.
Tailwinds
- Healthy core business growth of 8 to 10 percent in constant currency
- Raising U.S. Healthcare fiscal year 2025 sales target to $11 billion to $12 billion
- The U.S. Healthcare segment is expected to achieve positive adjusted EBITDA by fiscal year 2024.
- Reconfirmed expectation to achieve low-teens adjusted EPS growth in fiscal year 2025.
- Management will provide additional details during the earnings call presentation.
Headwinds
- Adverse currency movements of approximately 2 percent
- Headwind of 15 to 17 percent from lower COVID-19 vaccination volumes.
- Operating loss in the quarter reflects a $783 million non-cash impairment charge related to intangible assets in Boots UK.
- Operating loss in the quarter reflects higher costs related to the Transformational Cost Management Program.
- Adjusted operating income from continuing operations was $744 million, a decrease of 38.2 percent on a constant currency basis, reflecting lower U.S. pharmacy operating results as it lapped higher volumes of prior year COVID-19 vaccinations, and growth investments in U.S. Healthcare
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q4 2022
-0.1%
Avg return
Earnings day
+0.4%
Avg return
5 days after
-1.9%
Avg return
30 days after
53%
33 / 62 earnings
Positive
+29.1%
Q1 2025
Best reaction
-22.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.4% | +1.5% | +2.7% | |
| Q2 2025 | -1.1% | +0.5% | +4.1% | |
| Q1 2025 | +29.1% | +36.1% | +10.0% | |
| Q4 2024 | +23.0% | +18.7% | -2.0% | |
| Q3 2024 | -22.7% | -26.0% | -24.5% | |
| Q2 2024 | -7.0% | -10.9% | -15.7% | |
| Q1 2024 | -2.2% | -0.6% | -11.4% | |
| Q4 2023 | +2.9% | +2.1% | -7.3% | |
| Q3 2023 | -7.9% | -10.2% | -3.0% | |
| Q2 2023 | +3.7% | +5.0% | +6.6% | |
| Q1 2023 | -2.3% | -2.1% | -1.1% | |
| Q4 2022 | +4.1% | +3.8% | +29.4% | |
| Q3 2022 | -5.7% | -5.7% | -2.9% | |
| Q2 2022 | -7.6% | -8.4% | -10.6% | |
| Q1 2022 | -0.3% | +0.6% | -10.0% | |
| Q4 2021 | +3.5% | +1.5% | +4.8% | |
| Q3 2021 | -8.4% | — | — | |
| Q2 2021 | +3.3% | — | — | |
| Q1 2021 | +5.1% | — | — | |
| Q4 2020 | +4.2% | — | — | |
| Q3 2020 | -5.1% | — | — | |
| Q2 2020 | -5.4% | — | — | |
| Q1 2020 | -7.8% | — | — | |
| Q4 2019 | +1.5% | — | — | |
| Q3 2019 | +4.4% | — | — | |
| Q2 2019 | -13.6% | — | — | |
| Q1 2019 | -8.2% | — | — | |
| Q4 2018 | +1.6% | — | — | |
| Q3 2018 | -9.4% | — | — | |
| Q2 2018 | -0.7% | — | — | |
| Q1 2018 | -3.4% | — | — | |
| Q4 2017 | -0.3% | — | — | |
| Q3 2017 | +1.6% | — | — | |
| Q2 2017 | -1.0% | — | — | |
| Q1 2017 | +0.1% | — | — | |
| Q4 2016 | +5.7% | — | — | |
| Q3 2016 | -3.6% | — | — | |
| Q2 2016 | -3.0% | — | — | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -11.9% | — | — | |
| Q3 2015 | +8.4% | — | — | |
| Q1 2014 | +4.9% | — | — | |
| Q2 2015 | +4.9% | — | — | |
| Q4 2013 | +4.9% | — | — | |
| Q1 2015 | +3.2% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +0.6% | — | — | |
| Q2 2014 | +1.0% | — | — | |
| Q3 2013 | -1.0% | — | — | |
| Q2 2013 | +0.4% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q3 2012 | -3.2% | — | — | |
| Q2 2012 | -1.9% | — | — | |
| Q1 2012 | +4.1% | — | — | |
| Q4 2011 | +0.4% | — | — | |
| Q3 2011 | -0.9% | — | — | |
| Q2 2011 | +1.8% | — | — | |
| Q1 2010 | +2.5% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q3 2010 | -0.1% | — | — | |
| Q2 2009 | +0.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro